Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Synthetic dimer drugs require multiple synthetic steps and liquid formulations that prevent ultra-cheap generic margins. Even so, Matthew O'Connor emphasizes that production costs remain lower than therapeutic antibodies, enabling massive batch manufacturing without challenging or exceeding standard bioprocessing equipment capacities.

Related Insights

Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

In biomanufacturing, purifying a product is a major cost. Using an organism that secretes the product directly into the media eliminates the need for cell lysis and reduces endotoxin concerns. This simplification of downstream processing can cut total production costs by 25-33%, a significant competitive advantage.

While the active pharmaceutical ingredient for semaglutide is abundant, the real bottleneck for generic supply is the specialized, regulated "fill and finish" process. This final assembly stage requires years to build capacity, potentially constraining the market's ability to meet surging demand.

The surge in use of compounded GLP-1s, costing about half the price of branded versions, demonstrates huge untapped demand. Patients are willing to accept manufacturing and safety risks for affordability, proving price is a major barrier to adoption.

A key barrier to complex peptide-antibody drugs is manufacturing (CMC). Current methods require separate synthesis and conjugation steps. A fully genetically encoded system—where the entire hybrid molecule is produced in a single cell line—would dramatically lower the barrier to entry and simplify manufacturing, unlocking new drug designs.

David Ricks highlights that oral peptide GLP-1s achieve only about 1% bioavailability due to gut acid breakdown, requiring bioprocess manufacturing. In contrast, chemically derived small molecules like Lilly's achieve 50% to 80% bioavailability. While synthesizing a GPCR agonist chemically without off-target effects is technically difficult, chemical synthesis offers far lower production costs and vastly easier scale.

Unlike many biologics that can be scaled exponentially, membrane proteins often have inherent expression limitations. This means that scaling up production is a linear, rather than exponential, process. This fundamental constraint directly impacts CMC strategy, facility planning, and the overall cost of goods for therapies relying on these complex proteins.

Although cyclodextrin building blocks are biological products generated by microbial enzymes, decades of commercial use in foods and solvents matured their extraction. This industrial scale allows modern therapeutics to source ultrapure starting materials cheaply at scale without investing in complex upstream fermentation development.

The technological ideal of a fully automated, continuous manufacturing process won't universally replace current methods. Instead, the industry will evolve a two-track system: complex products like cell and gene therapies will drive adoption of advanced tech, while standard antibodies will continue to rely on cost-effective, proven fed-batch platform processes.

Early-stage biotechs often build companies purely around novel scientific concepts while neglecting manufacturability and patient access. Thinking through manufacturability from day one ensures that complex biologics can actually be produced affordably and delivered to patients, preventing bioprocessing bottlenecks when transitioning candidates toward clinical and commercial development.